Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
Lung cancer is one of the deadliest and most common malignancies in the world, representing one of the greatest challenges in cancer treatment. Immunotherapy is rapidly changing standard treatment schedule and outcomes for patients with advanced malignancies. However, several ongoing studies are sti...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2019/7652014 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545422189527040 |
|---|---|
| author | Carmine Carbone Geny Piro Vincenzo Di Noia Ettore D’Argento Emanuele Vita Miriam Grazia Ferrara Sara Pilotto Michele Milella Giovanni Cammarota Antonio Gasbarrini Giampaolo Tortora Emilio Bria |
| author_facet | Carmine Carbone Geny Piro Vincenzo Di Noia Ettore D’Argento Emanuele Vita Miriam Grazia Ferrara Sara Pilotto Michele Milella Giovanni Cammarota Antonio Gasbarrini Giampaolo Tortora Emilio Bria |
| author_sort | Carmine Carbone |
| collection | DOAJ |
| description | Lung cancer is one of the deadliest and most common malignancies in the world, representing one of the greatest challenges in cancer treatment. Immunotherapy is rapidly changing standard treatment schedule and outcomes for patients with advanced malignancies. However, several ongoing studies are still attempting to elucidate the biomarkers that could predict treatment response as well as the new strategies to improve antitumor immune system response ameliorating immunotherapy efficacy. The complex of bacteria, fungi, and other microorganisms, termed microbiota, that live on the epithelial barriers of the host, are involved in the initiation, progression, and dissemination of cancer. The functional role of microbiota has attracted an accumulating attention recently. Indeed, it has been demonstrated that commensal microorganisms are required for the maturation, education, and function of the immune system regulating the efficacy of immunotherapy in the anticancer response. In this review, we discuss some of the major findings depicting bacteria as crucial gatekeeper for the immune response against tumor and their role as driver of immunotherapy efficacy in lung cancer with a special focus on the distinctive role of gut and lung microbiota in the efficacy of immunotherapy treatment. |
| format | Article |
| id | doaj-art-292c1bc9e8514baa937afd4f7e01b562 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-292c1bc9e8514baa937afd4f7e01b5622025-02-03T07:25:52ZengWileyMediators of Inflammation0962-93511466-18612019-01-01201910.1155/2019/76520147652014Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung CancerCarmine Carbone0Geny Piro1Vincenzo Di Noia2Ettore D’Argento3Emanuele Vita4Miriam Grazia Ferrara5Sara Pilotto6Michele Milella7Giovanni Cammarota8Antonio Gasbarrini9Giampaolo Tortora10Emilio Bria11Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ItalyComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ItalyComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ItalyComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ItalyComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ItalyComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ItalySection of Medical Oncology, Department of Medicine, University of Verona and University Hospital Trust, Verona, ItalySection of Medical Oncology, Department of Medicine, University of Verona and University Hospital Trust, Verona, ItalyUniversità Cattolica del Sacro Cuore, Rome, ItalyUniversità Cattolica del Sacro Cuore, Rome, ItalyComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ItalyComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ItalyLung cancer is one of the deadliest and most common malignancies in the world, representing one of the greatest challenges in cancer treatment. Immunotherapy is rapidly changing standard treatment schedule and outcomes for patients with advanced malignancies. However, several ongoing studies are still attempting to elucidate the biomarkers that could predict treatment response as well as the new strategies to improve antitumor immune system response ameliorating immunotherapy efficacy. The complex of bacteria, fungi, and other microorganisms, termed microbiota, that live on the epithelial barriers of the host, are involved in the initiation, progression, and dissemination of cancer. The functional role of microbiota has attracted an accumulating attention recently. Indeed, it has been demonstrated that commensal microorganisms are required for the maturation, education, and function of the immune system regulating the efficacy of immunotherapy in the anticancer response. In this review, we discuss some of the major findings depicting bacteria as crucial gatekeeper for the immune response against tumor and their role as driver of immunotherapy efficacy in lung cancer with a special focus on the distinctive role of gut and lung microbiota in the efficacy of immunotherapy treatment.http://dx.doi.org/10.1155/2019/7652014 |
| spellingShingle | Carmine Carbone Geny Piro Vincenzo Di Noia Ettore D’Argento Emanuele Vita Miriam Grazia Ferrara Sara Pilotto Michele Milella Giovanni Cammarota Antonio Gasbarrini Giampaolo Tortora Emilio Bria Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer Mediators of Inflammation |
| title | Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer |
| title_full | Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer |
| title_fullStr | Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer |
| title_full_unstemmed | Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer |
| title_short | Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer |
| title_sort | lung and gut microbiota as potential hidden driver of immunotherapy efficacy in lung cancer |
| url | http://dx.doi.org/10.1155/2019/7652014 |
| work_keys_str_mv | AT carminecarbone lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT genypiro lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT vincenzodinoia lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT ettoredargento lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT emanuelevita lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT miriamgraziaferrara lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT sarapilotto lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT michelemilella lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT giovannicammarota lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT antoniogasbarrini lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT giampaolotortora lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer AT emiliobria lungandgutmicrobiotaaspotentialhiddendriverofimmunotherapyefficacyinlungcancer |